硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

侯楠; 安然; 侯健

doi:10.3969/j.issn.1006-0111.2016.05.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

侯楠, 安然, 侯健

文章导航 > 药学实践与服务 > 2016 > 34(5): 459-462

侯楠, 安然, 侯健. 硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析[J]. 药学实践与服务, 2016, 34(5): 459-462. doi: 10.3969/j.issn.1006-0111.2016.05.020

引用本文:

HOU Nan, AN Ran, HOU Jian. Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 459-462. doi: 10.3969/j.issn.1006-0111.2016.05.020

Citation:

HOU Nan, AN Ran, HOU Jian. Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 459-462. doi: 10.3969/j.issn.1006-0111.2016.05.020

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

第二军医大学附属长征医院血液内科, 上海 200003

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

Department of Hemopathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

摘要: 目的探讨以硼替佐米为基础的方案治疗华氏巨球蛋白血症（Waldenström macroglobulinemia，WM）的临床疗效及安全性。方法回顾性分析2008年12月至2015年10月收治的15例采用以硼替佐米为基础方案治疗的WM患者的临床资料。其中1例采用硼替佐米+地塞米松（BD）方案，3例采用硼替佐米+地塞米松+美罗华（RBD）方案，11例采用硼替佐米+地塞米松+环磷酰胺（BCD）方案，评价上述三方案的疗效及不良反应，并进行生存分析。结果治疗的总反应率及主要反应率分别为93.3%和80%[其中完全缓解（CR）1例、非常好的部分缓解（VGPR）2例、部分缓解（PR）9例、微小反应（MR）2例]。不良反应包括胃肠道副作用（53.3%）、白细胞减少（20%）、感染（20%）及外周神经病变（26.7%）。随访时间为3~85个月（中位数21个月），无进展生存（PFS）时间为3~36个月（中位数21个月），1年的PFS率分别为83.3%。生存分析显示IPSSWM分级为高危组（P=0.015）及用药后治疗反应小于PR（P=0.024）是影响WM患者PFS的危险因素。结论以硼替佐米为基础的治疗方案可有效治疗WM患者，IPSSWM分级体系及治疗反应可作为判断以硼替佐米为基础的治疗方案的WM患者疾病进展预后的参考因素。
- 硼替佐米 /
- 华氏巨球蛋白血症 /
- 疗效分析
Abstract: Objective To summarize the clinical experience of bortezomib-based treatment for Waldenström macroglobulinemia and evaluate the therapeutic efficacy and safety. Methods The clinical data were collected for 15 patients with Waldenström macroglobulinemia receiving bortezomib-based treatment from December 2008 to October 2015.Three therapeutic regimens included BD (bortezomib and dexamethasone) in one case, RBD (bortezomib, rituximab and dexamethasone) in three cases and BCD (bortezomib, dexamethasone and cyclophosphamide) in eleven cases.Responses, adverse reactions and survival analysis were evaluated respectively. Results The overall response rate and major response rate were 93.3% and 80% including CR 1 case, VGPR 2 cases, PR 9 cases and MR 2 cases. The common adverse events included gastrointestinal (53.3%), leukopenia (20%), infection (20%) and peripheral neuropathy (26.7%). After a median follow-up of 21 (3-85) months, the median PFS (progression-free survival) time was 21 (3-36) months and 1 year PFS rate was 83.3%. Survival analysis showed that two prognostic risk factors related to PFS were high-risk group based on international prognostic scoring system for WM(IPSSWM)(P=0.015) and the low response to treatment (P=0.024). Conclusion Bortezomib-based therapeutic regimensexhibited significant efficacyfor patients with WM. IPSSWM and the responses to treatment can be usedto monitor the disease progression and evaluate the therapeutic result.
- bortezomib /
- Waldenströ /
- m macroglobulinemia

[1]	侯健,彭利晖. 华氏巨球蛋白血症:循证医学新进展及共识更新[J]. 解放军医学杂志, 2013,38(9):705-709.
[2]	Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome[J]. J Clin Oncol, 2014,32(25):2712-2717.
[3]	Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia[J]. Semin Oncol, 2003,30(2):110-115.
[4]	Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia[J]. Blood, 2009,113(18):4163-4170.
[5]	Anderson KC, Alsina M, Bensinger W, et al. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013[J]. J Natl Compr Canc Netw, 2012,10(10):1211-1219.
[6]	Pascal L, Gay J, Willekens C, et al. Bortezomib and Waldenström's macroglobulinemia[J]. Expert Opin Pharmacother, 2009,10(5):909-916.
[7]	Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib[J]. Haematologica, 2005,90(12):1655-1658.
[8]	Treon SP, Hunter ZR, Matous J, et al.Multicenter clinical trial of bortezomib in relapsed/refractory Waldenström's macroglobulinemia: results of WMCTG Trial 03-248[J]. Clin Cancer Res, 2007,13(11):3320-3325.
[9]	Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007,25(12):1570-1575.
[10]	Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia[J]. Clin Lymphoma Myeloma, 2009,9(1):74-76.
[11]	Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180[J]. J Clin Oncol, 2009,27(23):3830-3835.
[12]	Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia[J]. J Clin Oncol, 2010,28(8):1422-1428.
[13]	Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia[J]. Am J Hematol, 2010,85(9):670-674.
[14]	Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial[J]. Blood, 2007,110(10):3557-3560.
[15]	Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib[J]. J Clin Oncol, 2006,24(19):3113-3120.
[16]	Yi S, Cui R, Li Z, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia[J]. Chin Med J (Engl), 2014,127(12):2327-2331.

[1]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
[2]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[3]	瞿文君, 白若楠, 崔力, 周琰. 基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 1-4. doi: 10.12206/j.issn.2097-2024.202401002
[4]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[5]	尹小娟, 台力丽, 肖俊峰, 季波. 铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
[6]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050

点击查看大图

计量

文章访问数: 3192
HTML全文浏览量: 366
PDF下载量: 485
被引次数: 0

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

第二军医大学附属长征医院血液内科, 上海 200003

收稿日期: 2016-05-18
修回日期: 2016-07-18

关键词:

硼替佐米 /

华氏巨球蛋白血症 /

疗效分析

摘要: 目的探讨以硼替佐米为基础的方案治疗华氏巨球蛋白血症（Waldenström macroglobulinemia，WM）的临床疗效及安全性。方法回顾性分析2008年12月至2015年10月收治的15例采用以硼替佐米为基础方案治疗的WM患者的临床资料。其中1例采用硼替佐米+地塞米松（BD）方案，3例采用硼替佐米+地塞米松+美罗华（RBD）方案，11例采用硼替佐米+地塞米松+环磷酰胺（BCD）方案，评价上述三方案的疗效及不良反应，并进行生存分析。结果治疗的总反应率及主要反应率分别为93.3%和80%[其中完全缓解（CR）1例、非常好的部分缓解（VGPR）2例、部分缓解（PR）9例、微小反应（MR）2例]。不良反应包括胃肠道副作用（53.3%）、白细胞减少（20%）、感染（20%）及外周神经病变（26.7%）。随访时间为3~85个月（中位数21个月），无进展生存（PFS）时间为3~36个月（中位数21个月），1年的PFS率分别为83.3%。生存分析显示IPSSWM分级为高危组（P=0.015）及用药后治疗反应小于PR（P=0.024）是影响WM患者PFS的危险因素。结论以硼替佐米为基础的治疗方案可有效治疗WM患者，IPSSWM分级体系及治疗反应可作为判断以硼替佐米为基础的治疗方案的WM患者疾病进展预后的参考因素。

English Abstract

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

Department of Hemopathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

Received Date: 2016-05-18
Rev Recd Date: 2016-07-18

Keywords:

Abstract: Objective To summarize the clinical experience of bortezomib-based treatment for Waldenström macroglobulinemia and evaluate the therapeutic efficacy and safety. Methods The clinical data were collected for 15 patients with Waldenström macroglobulinemia receiving bortezomib-based treatment from December 2008 to October 2015.Three therapeutic regimens included BD (bortezomib and dexamethasone) in one case, RBD (bortezomib, rituximab and dexamethasone) in three cases and BCD (bortezomib, dexamethasone and cyclophosphamide) in eleven cases.Responses, adverse reactions and survival analysis were evaluated respectively. Results The overall response rate and major response rate were 93.3% and 80% including CR 1 case, VGPR 2 cases, PR 9 cases and MR 2 cases. The common adverse events included gastrointestinal (53.3%), leukopenia (20%), infection (20%) and peripheral neuropathy (26.7%). After a median follow-up of 21 (3-85) months, the median PFS (progression-free survival) time was 21 (3-36) months and 1 year PFS rate was 83.3%. Survival analysis showed that two prognostic risk factors related to PFS were high-risk group based on international prognostic scoring system for WM(IPSSWM)(P=0.015) and the low response to treatment (P=0.024). Conclusion Bortezomib-based therapeutic regimensexhibited significant efficacyfor patients with WM. IPSSWM and the responses to treatment can be usedto monitor the disease progression and evaluate the therapeutic result.

引用本文: